| Literature DB >> 31871299 |
René Bruno1, Dean Bottino2, Dinesh P de Alwis3, Antonio T Fojo4, Jérémie Guedj5, Chao Liu6, Kristin R Swanson7, Jenny Zheng8, Yanan Zheng9, Jin Y Jin10.
Abstract
There is a need for new approaches and endpoints in oncology drug development, particularly with the advent of immunotherapies and the multiple drug combinations under investigation. Tumor dynamics modeling, a key component to oncology "model-informed drug development," has shown a growing number of applications and a broader adoption by drug developers and regulatory agencies in the past years to support drug development and approval in a variety of ways. Tumor dynamics modeling is also being investigated in personalized cancer therapy approaches. These models and applications are reviewed and discussed, as well as the limitations and issues open for further investigations. A close collaboration between stakeholders like clinical investigators, statisticians, and pharmacometricians is warranted to advance clinical cancer therapeutics. ©2019 American Association for Cancer Research.Entities:
Year: 2019 PMID: 31871299 DOI: 10.1158/1078-0432.CCR-19-0287
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531